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Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are dystrophinopathies, rare disorders characterized by progressive muscle weakness due to X-linked mutations of the dystrophin gene, leading to reduced/dysfunctional dystrophin production. 1 Clinical characteristics of the most severely affected include loss of ambulation and cardiopulmonary distress and potentially reduced life span. Although incurable, management and treatment options have improved the life span of individuals with dystrophinopathies. 1 Dystrophinopathies are associated with high health care costs and long-term disability, making them an important focus for population-level surveillance and intervention efforts, yet they are difficult to study. 2 Studies of muscular dystrophy are an early example of research prompted by advocacy efforts. In 2001, the US Congress amended the Public Health Service Act to authorize the Muscular Dystrophy Community Assistance, Research, and Education Act (MD-CARE Act) (reauthorized in 2008, 2014) . The MD-CARE Act legislated the establishment of a National Epidemiology Program by the Centers for Disease Control and Prevention (CDC) for "carrying out epidemiological activities regarding Duchenne and other forms of muscular dystrophies, including collecting and analyzing information on the number, incidence, correlates, and symptoms of cases." In response to the MD-CARE Act, the CDC created the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet) in 2002 to conduct population-based medical record surveillance of dystrophinopathies. 3 MD STARnet is a population-based surveillance program that collects information on the health status of the total population with dystrophinopathy in specific areas of the United States. The data sources for MD STARnet include neuromuscular clinics, hospitals and hospital discharge databases, private physicians, specialized clinics, service units for children with special health care needs, birth defects surveillance programs, and birth and death certificates. This is a unique network as other networks have concentrated their effort on a variety of issues in the population served by clinics. For example, the Cooperative International Neuromuscular Research Group (CINRG) works on observational studies, clinical trials, and post-marketing surveillance. 4 The Translational Research in Europe for the Assessment and Treatment of Neuromuscular Diseases (TREAT NMD) is a large international network of academic institutions, patient groups, and pharmaceutical companies covering a variety of aspects related to research and treatment of these diseases. 5 TREAT NMD seeks to standardize patient registries, organize patient databases and biobanks for clinical trials, produce treatment guidelines for standards of care, develop international consensus on animal and cellular models of neuromuscular diseases, standardize outcome measures, and produce consensus statements on clinical diagnosis and treatment protocols. The research activities of TREAT NMD include clinical trials, epidemiology, natural history, surveillance, genotype/phenotype analysis, and health care services. 5 Finally, the Canadian Neuromuscular Disease Registry (CNDR) is a network of clinics and investigators, part of the TREAT NMD network, whose main activity is to plan and recruit patients for clinical trials. They also conduct epidemiologic and natural history studies. 6 This article summarizes the first 15 years of clinical and public health contributions of MD STARnet in relation to the MD-CARE Act. This summary is presented in a format relevant to clinicians, patients, and advocacy groups.
Design Considerations for Surveillance
Pediatric-onset dystrophinopathies were ascertained for MD STARnet using International Classification of Diseases (ICD) codes (ICD-9: 359.1; ICD-10: G71.0) and other criteria in a population-based cohort from 6 sites (Arizona [ , and pediatric onset (diagnosed before age 21 years). 7, 8 Case definitions were created to assign diagnostic confidence (definite, probable, possible, manifesting female, or asymptomatic) based on clinical symptoms, clinical laboratory data, and/or evidence of X-linked family history ( Figure 1) . 9 Cases were further classified as DMD or BMD based on clinical presentation.
Abstractors were systematically trained to abstract relevant medical record data on all eligible cases. Clinical information was collected through medical record abstraction primarily from neuromuscular clinics. Authority for medical record review was obtained through state public health authority or institutional review board approval or exemption. 8 Data were quality checked, compiled, and deidentified prior to submission to the MD STARnet data coordinating center. From 2007 to 2012, selected primary caregivers and individuals with MD participated in voluntary survey research that collected information on personal experiences, such as quality of life, health care transition, and health care services (Table 1) .
MD STARnet has several strengths, including a populationbased approach to identify individuals with MD living within eligible catchment areas. 7 Clinical and laboratory data were extracted directly from medical charts and reviewed by neuromuscular specialists. This approach limits case misclassification, because eligibility for inclusion in MD STARnet is based on clinician review of relevant clinical and laboratory data. Despite these strengths, MD STARnet faces the typical limitations of rare disorder surveillance, namely, small sample size, diagnostic delays, and difficulties with case ascertainment. Additionally, retrospective medical record review may miss important factors that could have influenced the current health status of patients with DBMD but were not part of this record. Finally, although MD STARnet attempts to cover specific areas completely, the generalizability of the findings is compromised by the incomplete availability of clinical and vital information for individuals who migrate in or out of an MD STARnet surveillance region, and by the lack of electronic medical records for older individuals. It is also important to note that each primary or secondary study (eg, survey) based on the MD STARnet population has its own set of limitations depending on study design, sample size, the outcome selected, the availability of data, and the subpopulation examined.
Findings
As of October 2017, 31 peer-reviewed journal articles have been published on behalf of MD STARnet (Table 2 ). This narrative summarizes selected analytical findings from these papers.
Epidemiologic Insights
The first population-based prevalence estimates of pediatriconset dystrophinopathies in the United States were reported by MD STARnet. 8 A prevalence estimate of 1.38 per 10 000 was published in 2010 based on 649 males with a definite or probable diagnosis from each of the 6 sites. Prevalence was higher for Hispanic than non-Hispanic white or non-Hispanic black males and for DMD compared to BMD. 8 
Genetic Testing
Genetic information is increasingly necessary for clinical trials and estimating the numbers of individuals with various mutations who may be eligible for specific molecular therapies. In recent years, genetic testing for diagnosing mutations in the DMD gene has increased across MD STARnet sites. 10 In a 2009 study of 470 males, 41 (8.7%) had no mutation analysis done, and a DMD mutation was documented for 345 individuals (73.4%); the remaining 84 individuals (17.9%) had inconclusive or insufficient information. Of the mutations, deletions were the most common (n ¼ 270, 78.3%), followed by duplications (n ¼ 39, 11.3%) and point mutations (n ¼ 36, 10.4%).
Diagnostic Process and Disease Progression
Delays in diagnosing a rare disorder provide challenges in developing and implementing early interventions that may reduce disease severity. The retrospective cohort design of MD STARnet has allowed for studies of the diagnostic process. Earlier onset of symptoms was associated with earlier loss of ambulation (LOA); early signs and symptoms were identified as a risk factor for a more rapid progression of muscle weakness, as measured by age of LOA, after controlling for corticosteroid use, family history of dystrophinopathy, birth year, race/ethnicity, and MD STARnet site. There was a 10% reduction in the risk of loss of ambulation for every year of age before symptoms appear.
(continued) Specifically, a study of diagnostic delay among males without family history of a neuromuscular disorder showed an average delay of 2.5 years from first signs and symptoms (mean age 2.5 years) to a definitive diagnosis (mean age 4.9 years). 11 Another study reported on racial and ethnic disparities in the diagnostic process, with non-Hispanic black and Hispanic males evaluated later than non-Hispanic white males. 13 Diagnosis of a pediatric-onset dystrophinopathy in a male child also appeared to influence future reproductive patterns. Birth certificate data were linked within 3 MD STARnet sites to construct reproductive histories. 15 Based on these histories, 40% of mothers had another live birth after the birth of their oldest affected male in MD STARnet, and 18% had a birth after the diagnosis of their affected child. These mothers were more likely to be younger and nonwhite compared to mothers with no live births after having a son diagnosed with pediatric-onset dystrophinopathy. 15 Characterizing patterns of disease progression is important for determining clinically meaningful endpoints to evaluate treatments. An analysis of 825 males in MD STARnet led to the observation that early onset of signs and symptoms (<18 months of age) was associated with earlier loss of ambulation than among those with later onset of signs and symptoms (>5 years of age). 27 Overall, there was a 10% reduction in annual risk of loss of ambulation (LOA) for every 1-year delay in onset of the appearance of symptoms. 27 In comparing 60 pairs of affected brothers, investigators found that the age at which ambulation ceased was similar, with a median difference of 2 months; however, age at onset of other outcomes, such as scoliosis (median difference of 8 months) and cardiomyopathy (median difference of 2 years), was more varied. 18 Growth US standard growth charts do not accurately reflect the growth trajectories of males with pediatric-onset dystrophinopathies due to characteristic muscle wasting and shortened stature. 17, 28 Therefore, MD STARnet investigators developed weight-, height-, and body mass index (BMI)-for-age growth charts for steroid-naïve, ambulatory males from heights and weights recorded at each neuromuscular clinic visit. 17 Comparisons of the dystrophinopathy-derived growth charts to the general US pediatric population illustrated that steroid-naïve, ambulatory males with a pediatric-onset dystrophinopathy were shorter and tended toward the extremes of weight and BMI than steroid-treated boys. 17 Furthermore, ambulatory males who were treated with steroids for at least 6 months were shorter than those who were steroid-naïve 28 ( Figure 2 ).
Corticosteroid Patterns of Use and Clinical Outcomes
As corticosteroids are often used to preserve functional status, MD STARnet examined corticosteroid treatment patterns including percentages of users, age at initiation, and dosing schedules. 9, 21 Among males born from 1984 to 1998 in 4 MD STARnet sites (AZ, CO, IA, wNY), the average percentage of males across all sites who had ever used corticosteroids was 47.1% in 2005, and the median dosages were 0.729 mg/kg for prednisone/prednisolone and 0.831 mg/kg for deflazacort. 9 A more recent analysis of corticosteroid use in 6 sites (IA, CO, GA, HI, IA, wNY) found that 60% of males had ever used corticosteroids, and recent birth cohorts tended to start steroid Findings from MD STARnet studies suggest variable associations between corticosteroid use and clinical outcomes. 24, 27, 34 Investigators who recently analyzed data from all 6 MD STARnet sites reported a complex association between duration of corticosteroid use and LOA, with lower annual risk of LOA among long-term (>3 years) users, but higher annual risk among short-term (0.25 > X < 3.0 years) users, compared to an untreated group. 24 Using data from 5 sites (IA, CO, GA, IA, wNY), Barber et al 16 reported delayed onset of cardiomyopathy among corticosteroid users. Further examination of timing of corticosteroid use showed that males who initiated treatment at 5 years of age or younger had a higher rate of fracture and earlier onset of cardiomyopathy compared to those who initiated steroid treatment after age 5 years. 34 These results point to a need for additional epidemiologic studies of treatment practices that minimize adverse events relating to steroid use, while optimizing clinical outcomes.
Neurobehavioral Comorbidities
Neurobehavioral comorbidities are of concern to individuals affected with a pediatric-onset dystrophinopathy and their families. In a sample of 765 oldest affected males, 45% had at least 1 documented neurobehavioral morbidity, which included behavior problems (43%), attention-deficit/hyperactivity disorder (23%), or a depressed mood (51%). Of the 344 males with at least 1 neurobehavioral concern, 69% received neuropsychiatric medication, counseling, or both; however, variability in the mode of interventions was found across type of neurobehavioral concern. 23 In addition to males with pediatric-onset dystrophinopathies, MD STARnet has described the symptom profiles of 9 manifesting females highlighting potential areas of intervention beyond neuromuscular management in this population, and noted neurobehavioral problems as a component of disease. 20 These findings emphasize the importance of comprehensive programs that support the neurobehavioral sequelae of individuals with pediatric-onset dystrophinopathies.
Multidisciplinary Care Recommendations
Individuals with pediatric-onset dystrophinopathy require multidisciplinary care that includes monitoring of neuromuscular, pulmonary, and cardiac systems. 25, 29 Data from interviews of caregivers of affected males followed through MD STARnet indicated patterns of cardiac care were more consistent with care recommendations than those for pulmonary care, and the types of specialists patients saw and services they received varied among sites. 25 MD STARnet surveillance data suggested that less than one-half of interviewed adolescents received the recommended biannual pulmonary function assessments, although approximately two-thirds had annual monitoring of hypoventilation. 29 
Scientific Impact and Future Directions
In addition to epidemiologic findings, MD STARnet data have provided important clinical information for use by federal and state agencies. Population-based frequencies of affected males under age 18 years from MD STARnet contributed to evidence used by the US Food and Drug Administration (FDA) to designate dystrophinopathy a rare pediatric condition. The US FDA also used MD STARnet data in its review process for a drug targeting a subpopulation of muscular dystrophy patients. Additionally, MD STARnet data has been used to estimate the number of potential DMD patients with varied genetic profiles who may be eligible for drug treatments.
Future clinical outcomes to be examined by MD STARnet will include survival, natural history of scoliosis, endocrine function, bone health, and left ventricular dysfunction among adults living with a dystrophinopathy diagnosis. In addition, surveillance has been expanded to collect epidemiologic and clinical information on limb girdle, congenital, facioscapulohumeral, myotonic, oculopharyngeal, distal, and Emery-Dreifuss muscular dystrophies. Future initiatives of MD STARnet may focus on tracking the implementation of newly developed ICD-11 codes for dystrophinopathies and facioscapulohumeral dystrophy.
Conclusion
MD STARnet has made important multidisciplinary contributions to pediatric-onset dystrophinopathy research -in epidemiology, early detection and diagnosis, genetic testing, growth, comorbidities, and disease management experiences of individuals living with dystrophinopathy. Current and future population-based surveillance efforts will continue to monitor clinical trajectories of individuals with muscular dystrophies in the US in accordance with the MD-CARE Act. 
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